3 completed, 2 unknown, 1 recruiting, 1 terminated. 7 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 3, Unknown 2, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Unknown 2, Terminated 1 |
Follow Blepharoptosis: new trials by email Literature Review of Blepharoptosis trials Research Report on Blepharoptosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Chinese Patients With Acquired Blepharoptosis STN1013800 ophthalmic solution, STN1013800 ophthalmic solution Liquid Base, without STN1013800 - Blepharoptosis | Phase 3 | Recruiting | Santen Pharmaceutical Co., Ltd. | 180 | 2024-10-22 | 2026-05-15 |
| Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis Oxymetazoline 0.1% (Pf) Oph Soln Ud, Preservative free lubricating drops - Blepharoptosis, Synkinesis | Phase 3 | Completed | Milton S. Hershey Medical Center | 36 | 2024-01-11 | 2026-03-09 |
| Fibrin Sealant in Eyelid Surgery Tisseel - Blepharoptosis, Ecchymosis; Eyelid | Phase 2 / Phase 3 | Unknown | University of Calgary | 30 | 2022-05-01 | 2022-05-03 |
| Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft Myoblast autologous graft - Muscular Dystrophy, Oculopharyngeal, Ptosis | Phase 2 / Phase 3 | Terminated | University Hospital, Caen | 1 | 2019-11-14 | 2020-11-25 |
| Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis RVL-1201, Vehicle ophthalmic solution - Blepharoptosis | Phase 3 | Completed | RVL Pharmaceuticals, Inc. | 164 | 2018-06-28 | 2020-09-16 |
| Study of Safety of RVL-1201 in Treatment of Blepharoptosis RVL-1201, Vehicle ophthalmic solution - Blepharoptosis | Phase 3 | Completed | RVL Pharmaceuticals, Inc. | 234 | 2018-06-20 | 2020-09-16 |
| Bupivacaine Injection of Eye Muscles to Treat Strabismus Bupivacaine - Strabismus, Esotropia | Phase 2 / Phase 3 | Unknown | Smith-Kettlewell Eye Research Institute | 120 | 2012-04-01 | 2019-09-23 |
Diplopia (1) · Ecchymosis (1) · Esotropia (1) · Exotropia (1) · Facial Paralysis (1) · Graves Disease (1) · Hyperkinesis (1) · Muscular Dystrophy, Oculopharyngeal (1) · Strabismus (1) · Synkinesis (1)
Eye Diseases (7) · Eyelid Diseases (7) · Nervous System Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Neurologic Manifestations (2) · Autoimmune Diseases (1) · Blood Coagulation Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Cranial Nerve Diseases (1) · Dyskinesias (1) · Endocrine System Diseases (1) · Exophthalmos (1) · Genetic Diseases, Inborn (1) · Goiter (1)
Bupivacaine (1) · Fibrin Tissue Adhesive (1) · Oxymetazoline (1)
RVL Pharmaceuticals, Inc. (2) · Milton S. Hershey Medical Center (1) · Santen Pharmaceutical Co., Ltd. (1) · Smith-Kettlewell Eye Research Institute (1) · University Hospital, Caen (1) · University of Calgary (1)
United States (4) · China (1) · France (1)
Alan B Scott, MD (1) · Frederic MF Mouriaux, PhD (1) · Jessyka Lighthall, MD (1) · Joel M Miller, PhD (1) · Karim Punja, MD (1) · Olivier BO Boyer, PhD (1) · Sophie PS Perie, PhD (1)
2015 (1)